sTREM-1, sIL-2Rα, and IL-6, but not sCD163, might predict sepsis in polytrauma patients: a prospective cohort study

Trancă, Sebastian; Oever, Jaap ten; Ciuce, Constantin; Netea, Mihai G.; Slavcovici, Adriana; Petrișor, Cristina; Hagău, Natalia

doi:10.1007/s00068-016-0678-1

Cited by 10 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the meta-analysis performed in 2012 covering eleven studies indicated that sTREM-1 in plasma determined individually was not a sufficient biomarker differentiating sepsis from SIRS [103]. In 2016, a cohort study indicated predictive value of sTREM-1 protein as an indicator for sepsis occurrence in patients suffering from polytrauma [104].…”

Section: Triggering Receptor Expressed On Myeloid Cells-1mentioning

confidence: 99%

Infection-induced innate antimicrobial response disorders: from signaling pathways and their modulation to selected biomarkers

Stelmasiak¹,

Słotwiński²

2020

cejoi

View full text Add to dashboard Cite

Severe infections are a major public health problem responsible for about 40-65% of hospitalizations in intensive care units (ICU). The high mortality (30-50%) of persons diagnosed with severe infection is caused by largely unknown mechanisms of sepsis-induced immune system response. Severe infections with dynamic progress are accompanied with SIRS (systemic inflammatory reaction syndrome) and CARS (compensatory anti-inflammatory response syndrome), and require a biological treatment appropriate to the phase of immune response. The mechanisms responsible for severe infection related to immune system response particularly attract extensive interest of non-specific defense mechanisms, including signaling pathways of Toll-like receptors (mainly TLR4 and TLR2) that recognize distinct pathogen-associated molecular patterns (PAMP) and play a critical role in innate immune response. There are attempts of treatment, followed by blocking ligand binding with TLR or modulation of intracellular signaling pathways, to inhibit signal transduction. Moreover, researches regarding new and more efficient diagnostics biomarkers were mostly focused on indicators related to innate response to infection as well as connections of pro-inflammatory response with anti-inflammatory response. According to these studies, in case of ICU septic patients with high-risk of mortality, the solution for the problem will require mainly early immune and genetic diagnostics (e.g. cytokines, microRNA,, triggering receptor expressed on myeloid cells-1 [TREM-1], and high mobility group box 1 protein [HMGB1]).

show abstract

Section: Triggering Receptor Expressed On Myeloid Cells-1mentioning

confidence: 99%

Infection-induced innate antimicrobial response disorders: from signaling pathways and their modulation to selected biomarkers

Stelmasiak¹,

Słotwiński²

2020

cejoi

View full text Add to dashboard Cite

show abstract

“…It is, however, not without its drawbacks. The test itself is expensive compared with CRP testing, and while PCT increases are more specific for bacterial infections than CRP or ESR, false-positive results may be observed in such cases as acute respiratory distress syndrome, chemical pneumonitis, severe falciparum malaria, and others ( 32 ). It is important to note that trauma and subsequent tissue damage may, and often do, induce sepsis via release of inflammatory compounds and subsequent perpetuation of the immune response.…”

Section: Procalcitonin and C-reactive Proteinmentioning

confidence: 99%

“…It is important to note that trauma and subsequent tissue damage may, and often do, induce sepsis via release of inflammatory compounds and subsequent perpetuation of the immune response. However, high values for biomarkers other than PCT are more indicative of classical bacterial sepsis than trauma ( 32 ). This is at least partially because PCT rises higher in correlation with the severity of an infection, whereas CRP quickly reaches a plateau no matter the source or comparative severity of inflammation ( 33 ).…”

Section: Procalcitonin and C-reactive Proteinmentioning

confidence: 99%

A Novel Combination of Biomarkers to Herald the Onset of Sepsis Prior to the Manifestation of Symptoms

Dolin

Papadimos²,

Stepkowski³

et al. 2018

Shock

View full text Add to dashboard Cite

Sepsis, which kills over 200,000 patients and costs over $20 billion in the United States alone, presents a constant but preventable challenge in the healthcare system. Among the more challenging problems that it presents is misdiagnosis due to conflation with other inflammatory processes, as its mechanisms are identical to those of other inflammatory states. Unfortunately, current biomarker tests can only assess the severity and mortality risk of each case, whereas no single test exists that can predict sepsis prior to the onset of symptoms for the purpose of pre-emptive care and monitoring. We propose that a single test utilizing three, rather than two, biomarkers that appear most quickly in the blood and are the most specific for sepsis rather than trauma, may improve diagnostic accuracy and lead to lessened patient morbidity and mortality. Such a test would vastly improve patient outcomes and quality of life, prevent complications for sepsis survivors, and prevent hospital readmissions, saving the American healthcare system money. This review summarizes the current use of sepsis biomarkers to prognosticate morbidity and mortality, and rejects the current single-biomarker and even combination biomarker tests as non-specific and inaccurate for current patient needs/pro-inflammatory cytokines, general markers of inflammation, and proteins specific to myeloid cells (and therefore to infection) are discussed. Ultimately, the review suggests a three-biomarker test of procalcitonin (PCT), interleukin-6 (IL-6), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to diagnose sepsis before the onset of symptoms.

show abstract

“…Thus, combination therapy with checkpoint inhibitors may provide a viable solution for enhancing the antitumor effect of the CAR T-cells, as it was proven by the team of O’Rourke et al in solid malignancies ( 140 ). A good strategy would be to develop the so-called armored CARs, which also express the very efficient cytokine IL-12, which has a pleiotropic on both innate and adaptive T lymphocytes ( 141 ). To further augment the antitumor activity, the fourth-generation CAR that contains a transduction domain to promote production of a T-cell-activating cytokine such as IL-12 (so-called armored CAR T) are currently being researched ( 174 , 175 ).…”

Section: Genetic Engineered T-cells For the Immunotherapy Of Allmentioning

confidence: 99%

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

et al. 2018

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell technology has seen a rapid development over the last decade mostly due to the potential that these cells may have in treating malignant diseases. It is a generally accepted principle that very few therapeutic compounds deliver a clinical response without treatment-related toxicity, and studies have shown that CAR T-cells are not an exception to this rule. While large multinational drug companies are currently investigating the potential role of CAR T-cells in hematological oncology, the potential of such cellular therapies are being recognized worldwide as they are expected to expand in the patient to support the establishment of the immune memory, provide a continuous surveillance to prevent and/or treat a relapse, and keep the targeted malignant cell subpopulation in check. In this article, we present the possible advantages of using CAR T-cells in treating acute lymphoblastic leukemia, presenting the technology and the current knowledge in their preclinical and early clinical trial use. Thus, this article first presents the main present-day knowledge on the standard of care for acute lymphoblastic leukemia. Afterward, current knowledge is presented about the use of CAR T-cells in cancer immunotherapy, describing their design, the molecular constructs, and the preclinical data on murine models to properly explain the background for their clinical use. Last, but certainly not least, this article presents the use of CAR T-cells for the immunotherapy of B-cell acute lymphoblastic leukemia, describing both their potential clinical advantages and the possible side effects.

show abstract

sTREM-1, sIL-2Rα, and IL-6, but not sCD163, might predict sepsis in polytrauma patients: a prospective cohort study

Abstract: Level II-Diagnostic tests and criteria.

Cited by 10 publications

References 35 publications

Infection-induced innate antimicrobial response disorders: from signaling pathways and their modulation to selected biomarkers

Infection-induced innate antimicrobial response disorders: from signaling pathways and their modulation to selected biomarkers

A Novel Combination of Biomarkers to Herald the Onset of Sepsis Prior to the Manifestation of Symptoms

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About